First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews : Anti-Cancer Drugs

Journal Logo

Case report

First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews

Wu, Rongronga,*; Liu, Shinanb,*; Lv, Guolib; Deng, Chaowenb; Wang, Ruolanb; Zhang, Shenglinb; Zhu, Dongyib; Wang, Leb; Lei, Youmingc; Luo, Zhuangb

Author Information
Anti-Cancer Drugs ():10.1097/CAD.0000000000001408, November 16, 2022. | DOI: 10.1097/CAD.0000000000001408

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid